Connect with us

Headlines

FDA Recalls Online Vision Test

The company was formerly known as Opternative.

mm

Published

on

The Visibly Online Refractive Vision Test has been recalled by the U.S. Food and Drug Administration.

The test by Visibly, formerly known as Opternative, “is being recalled since the firm has not received authorization from FDA to market the product,” according to a notice from the FDA.

The FDA states that the test has had worldwide distribution, including including Arizona, California, Delaware, Florida, Illinois, Missouri, Nevada, New York, Ohio, Pennsylvania, Texas, Washington and Utah.

What’s Really Up with Vision Expo in 2021?
INVISION Podcast

What’s Really Up with Vision Expo in 2021?

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop
INVISION Podcast

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]
INVISION Podcast

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]

Healio.com notes that the FDA sent a warning letter to Opternative in 2017. The news site reports that the company did not respond to a request for comment on the recall.

The American Optometric Association states that in April 2016, it “issued a formal complaint to the FDA that emphasized Opternative’s lack of premarket approval (PMA) prior to marketing. The organization says it “indicated that the test should be removed from the market altogether.”

AOA states that it had concerns about “the potential for inaccurate prescriptions, missed diagnoses of serious and general health conditions, and the creation of a prescription with little input from an eye doctor.”

Advertisement

“Optometrists and other physicians know that eye exams are essential care and that new health technologies must always enhance the doctor-patient relationship and help deliver improved outcomes,” said AOA President Barbara L. Horn, OD. “They must also comply with the law — that’s exactly what the AOA and our state associations have insisted on through the information we provided to the FDA and other agencies in this matter, and we’re proud that it appears to have made a difference.”

The action is a Class 2 recall, meaning the FDA considers it “a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

The FDA explains that recall is “a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective.”

SPONSORED VIDEO

Sponsored by Shamir

Customer Focused, Service Oriented, Forward Thinking

Shamir is the recognized world leader in custom-designed technology for life improvement, fashion, performance sports, occupational single vision, and progressive lenses. Our values, the driving force behind our ideas and actions, keep the ECP in the center. Every Shamir representative is personally committed to our customers’ vision, and to providing the best service and support to meet and exceed their expectations, all with a personal touch.

Click here for more information.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular